Solid tumors mainly include but are not limited to advanced lung cancer, esophageal cancer and colorectal cancer
Conditions
Interventions
experimental group:CD276-targeted chimeric antigen receptor T cells
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subjects who were confirmed as target tumor by histopathology; 2. Subjects aged > 18 years and 40 kg 3. The subjects who signed the written informed consent; 4. Subjects without severe viral or bacterial infection; 5. Patients expected to survive > 1 year.
Exclusion criteria
Exclusion criteria: 1. Subjects currently participating in another clinical trial; 2. Subjects treated with immunosuppressant; 3. Subjects with autoimmune diseases; 4. Subjects with clinically related diseases or infections (HBV, HCV, HIV); 5. Patients with previous history of other malignant tumors or other active malignant tumors requiring treatment in the same period. 6. Subjects with allergic constitution and multi drug allergy were excluded; 7. Women in pregnancy were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SAE rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| CR, PR, SD, PD;progression free survival and overall survival; | — |
Countries
China
Contacts
Public ContactYi Zhang
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed